MYB proto-oncogene like 2Genealiases: B-MYB · BMYB
Q-omics provides the consensus-scored MYBL2 profile across patient tissues and cancer cell-line models. MYBL2 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MYBL2 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, MYBL2 RNA expression shows 25,984 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, HNSC, and LUAD as cancer lineages where MYBL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYBL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYBL2 survival associations across molecular data types. MYBL2 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYBL2 RNA expression–survival associations across cancer types. High MYBL2 expression shows unfavorable associations in ACC, KIRP, MESO, KIRC, LIHC and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MYBL2 RNA expression.
This table summarizes MYBL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MYBL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYBL2 shows higher tumor expression in HNSC, COAD, LUAD, KIRP, BLCA and KIRC. The HNSC box plot shows higher MYBL2 RNA expression in tumor versus normal tissue (log2 FC = +3.010, t-test p < 0.001).
This table shows molecular features associated with MYBL2 in patient tissues and cancer cell lines. In patient samples, MYBL2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MYBL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
